| Literature DB >> 32175703 |
Mazin Barry1, Maha Al Amri2, Ziad A Memish3,4,5.
Abstract
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has plagued the Middle East since it was first reported in 2012. Recently, at the end of December 2019, a cluster of pneumonia cases were reported from Wuhan city, Hubei Province, China, linked to a wet seafood market with a new coronavirus identified as the etiologic agent currently named SARS-CoV-2. Most cases are in Mainland China with international spread to 25 countries. The novelty of the virus, the rapid national and international spread, and the lack of therapeutic and preventative strategies have led the WHO International Health Regulation emergency committee to declare the disease as Public Health Emergency of International Concern (PHEIC) on January 30, 2020. As it relates to countries with the ongoing MERS-CoV community cases and hospital acquired infections, there will be a huge challenge for HCWs to deal with both coronaviruses, especially with the lack of standardized and approved point of care testing. This challenge will now be faced by the whole global health community dealing with COVID-19 since both coronaviruses have similar presentation. Those patients should now be tested for both MERS-CoV and SARS-CoV-2 simultaneously, and with the continuing wide international spread of SARS-CoV-2, the travel history to China in the last 14 days will be of less significance.Entities:
Keywords: COVID-19; MERS-CoV; SARS-CoV-2; Saudi Arabia
Mesh:
Year: 2020 PMID: 32175703 PMCID: PMC7310806 DOI: 10.2991/jegh.k.200218.003
Source DB: PubMed Journal: J Epidemiol Glob Health ISSN: 2210-6006
Figure 1Countries, territories, or areas with reported confirmed cases of 2019-nCoV, February 11, 2020
Chinese CDC epidemiological and clinical criteria definitions
| Clinical criteria
Fever Existence of pneumonia on chest X-ray Normal or decreased white blood cell count Decreased lymphocyte count |
WHO suspected case definition for COVID-19
|
Patient with severe acute respiratory infection (fever, cough and requiring admission to the hospital) AND there is no other etiology that fully explains the clinical presentation AND a history of travel to or residence in China during the 14 days prior to symptoms onset Patient with any acute respiratory illness AND at least one of the following during the 14 days prior to symptoms onset:
Contact with a confirmed or probable case of COVID-19 infection or Worked in or attended a health-care facility where patients with confirmed or probable COVID-19 acute respiratory disease patients were being treated |
MERS-CoV case definition for suspected case as per the command and control center
Severe pneumonia (severity score ≥3 points) or ARDS (based on clinical or radiological evidence) Unexplained deterioration of a chronic condition of patients with congestive heart failure or chronic kidney disease on hemodialysis Acute febrile illness ( Gastrointestinal symptoms (diarrhea or vomiting) AND leukopenia (white blood cell ≤3.5 × 109/L) OR thrombocytopenia (platelets <150 × 109/L) |
Exposure to a confirmed case of MERS-CoV infection Visit to a health-care facility where MERS-CoV patient(s) has recently (within 2 weeks) been identified/treated Contact with dromedary camels or consumption of camel products (e.g., raw meat, unpasteurized milk, urine) |
In adults and does not need an epidemiological criterion.
In adult and children and both need an epidemiological link within 14 days before symptoms onset.
ARDS, Acute Repiratory Distress Syndrome.